Back to Search Results
Image Place holder

Robert Wenham, MD, MS, FACOG, FACS

Chair, Department of Gynecologic Oncology

★★★★★
★★★★★
4.9 (116 ratings)
Specialty: Gynecologic Oncology
Sub Specialty: Gynecologic Oncology
Program: Gynecologic Oncology

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Cervical Cancer, Endometrial (Uterine) Cancer, Ovarian Cancer, Vaginal Cancer, Vulvar Cancer

Dr. Robert Wenham is a gynecologic oncologist and Chair of the Gynecologic Oncology Program at Moffitt Cancer Center.  Dr. Wenham has a strong interest in research and is a principal investigator for numerous clinical trials to improve cancer care for women.  His research activities include the use of novel drugs for the treatment of gynecologic cancers.  He has received the Molly Cade Ovarian Cancer Research Award from the Gynecologic Cancer Foundation.  Dr. Wenham enjoys the challenge of helping women with complex issues and the opportunity to offer them cutting-edge therapies, from the latest chemotherapy approaches to biological targeted therapies, minimally invasive surgery and clinical trials.  He is also an expert in pelvic exenterative surgery,  a very complex operation that offers hope of possible cure for certain patients with gynecologic cancer.  Clinically, he prefers a more collaborative approach where the patient plays an active role in decisions as he guides them through the pros and cons of their options.  The future of gynecologic oncology is exciting as the rapid pace of translational research is changing the outcome and quality of life for patients.  Dr. Wenham points out that life expectancy for certain women’s cancers, such as ovarian cancer, have dramatically improved over the last 30 years and continue to improve at an encouraging rate.  Recently, Dr. Wenham was voted by physician peers as one of the top gynecologic oncologists (Tampa Magazine, Dec/Jan 2017).  Dr. Wenham also sees patients at Moffitt Cancer Center at International Plaza.


Education & Training

Fellowship:

  • Duke University Medical Center - Gynecologic Oncology

Residency:

  • Harvard, Brigham and Women's Hospital and Massachusetts General Hospital - Combined Program of Obstetrics and Gynecology

Medical School:

  • University of Texas Southwestern Medical School - MD
Participating Trials

CLINICAL TRIAL 20187
Development of Intra-tumor Driver Mutation Prevalence as a Predictor of Efficacy of Targeted Agents
Condition: Gynecological Tumor
Intervention:
Open

CLINICAL TRIAL 18959
A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Cervical Carcinoma
Condition: Gynecological Tumor
Intervention: Fluconazole (); IL-2 (Interleukin-2); LN-145 (); MESNA (); Neupogen (filgrastim); Pembrolizumab (Keytruda); cyclophosphamide (); cytoxan (cyclophosphamide); filgrastim (); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 20848
Phase I/II Study of REGN5668 (MUC16 x CD28, A Costimulatory Bispecific) Administered In Combination With Cemiplimab or REGN4018 (MUC16 x CD3)
Condition: Gynecological Tumor
Intervention: Cemiplimab (); REGN2810 (Cemiplimab); REGN4018 (); REGN5668 ()
Open

CLINICAL TRIAL 21113
A Phase I Clinical Trial of an Infusion of Autologous T Cells Genetically Engineered with a Chimeric Receptor to Target the Follicle-Stimulating Hormone Receptor in Patients with Recurrent Ovarian Cancer
Condition: Gynecological Tumor
Intervention: FSHR T-Cells (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 20497
A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability and Efficacy of MORAb-202, a Folate Receptor Alpha (FRA)-Targeting Antibody-Drug Conjugate (ADC) in Subjects with Selected Tumor Types
Condition: Gynecological Tumor
Intervention: MORAb-202 ()
Open

CLINICAL TRIAL 21870
A Phase 2 trial of Nirogacestat in Patients with Recurrent Ovarian Granulosa Cell Tumors
Condition: Gynecological Tumor
Intervention: Nirogacestat ()
Open

CLINICAL TRIAL 21901
Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors (MAGNETIC Study)
Condition: Gynecological Tumor
Intervention: Gemzar (gemcitabine); RP-6306 (); gemcitabine ()
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Herzog TJ, Pignata S, Ghamande SA, Rubio MJ, Fujiwara K, Vulsteke C, Armstrong DK, Sehouli J, Coleman RL, Gabra H, Scambia G, Monk BJ, Arranz JA, Ushijima K, Hanna R, Zamagni C, Wenham RM, González-Martín A, Slomovitz B, Jia Y, Ramsay L, Tewari KS, Weil SC, Vergote IB. Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer. Gynecol Oncol. 2023 Mar.170:300-308. Pubmedid: 36758420.
  • Tanyi JL, Randall LM, Chambers SK, Butler KA, Winer IS, Langstraat CL, Han ES, Vahrmeijer AL, Chon HS, Morgan MA, Powell MA, Tseng JH, Lopez AS, Wenham RM. A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006). J Clin Oncol. 2023 Jan.41(2):276-284. Pubmedid: 36070540.
  • Fermin O, Delgado A, Sarkar P, Chern JY, Wenham R, Hoffman MS. Vaginal Evisceration Subsequent to Hysterectomy at a Major Cancer Center. J Gynecol Surg. 2023 Feb.39(1).
  • Anadon CM, Yu X, Hänggi K, Biswas S, Chaurio RA, Martin A, Payne KK, Mandal G, Innamarato P, Harro CM, Mine JA, Sprenger KB, Cortina C, Powers JJ, Costich TL, Perez BA, Gatenbee CD, Prabhakaran S, Marchion D, Heemskerk MHM, Curiel TJ, Anderson AR, Wenham RM, Rodriguez PC, Conejo-Garcia JR. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell. 2022 May.40(5):545-557.e13. Pubmedid: 35427494. Pmcid: PMC9096229.
  • Martin AL, Sinha S, Peres LC, Hakam A, Chon HS, Hoffman MS, Shahzad MM, Wenham RM, Chern JY. The impact of distance to closest negative margin on survival after pelvic exenteration. Gynecol Oncol. 2022 Jun.165(3):514-521. Pubmedid: 35487774.
  • Chan JK, Tian C, Kesterson JP, Monk BJ, Kapp DS, Davidson B, Robertson S, Copeland LJ, Walker JL, Wenham R, Casablanca Y, Spirtos NM, Tewari KS, Bell JG. In Reply. Obstet Gynecol. 2022 Jun.139(6):1196-1197. Pubmedid: 35675622.
  • Martin AL, Anadon CM, Biswas S, Mine JA, Handley KF, Payne KK, Mandal G, Chaurio RA, Powers JJ, Sprenger KB, Rigolizzo KE, Innamarato P, Harro CM, Mehta S, Perez BA, Wenham RM, Conejo-Garcia JR. Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors. Mol Cancer Ther. 2022 Jul.21(7):1184-1194. Pubmedid: 35499393. Pmcid: PMC9256805.
  • Chan JK, Tian C, Kesterson JP, Monk BJ, Kapp DS, Davidson B, Robertson S, Copeland LJ, Walker JL, Wenham RM, Casablanca Y, Spirtos NM, Tewari KS, Bell JG. Symptoms of Women With High-Risk Early-Stage Ovarian Cancer. Obstet Gynecol. 2022 Feb.139(2):157-162. Pubmedid: 34991145. Pmcid: PMC9126568.
  • Chan JK, Tian C, Kesterson JP, Richardson MT, Lin K, Tewari KS, Herzog T, Kapp DS, Monk BJ, Casablanca Y, Hanjani P, Wenham RM, Walker J, McNally L, Copeland LJ, Robertson S, Lentz S, Spirtos NM, Bell JG. The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study. Gynecol Oncol. 2022 Dec.167(3):429-435. Pubmedid: 36244828.
  • Fu S, Corr BR, Culm-Merdek K, Mockbee C, Youssoufian H, Stagg R, Naumann RW, Wenham RM, Rosengarten RD, Benjamin L, Hamilton EP, Moore KN. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2022 Aug.40(23):2568-2577. Pubmedid: 35439029. Pmcid: PMC9362870.
  • Kuznicki ML, Mallen A, Ha K, McClung EC, Castaneda AV, Cao B, Fridley BL, Chon HS, Chern JY, Hoffman M, Wenham RM, Matsuo K, Shahzad MMK. Prognostic features of endometrial cancer metastasis to the central nervous system. PLoS One. 2022 Aug.17(8):e0268794. Pubmedid: 36018828. Pmcid: PMC9417007.
  • Saeed-Vafa D, Marchion DC, McCarthy SM, Hakam A, Lopez A, Wenham RM, Apte SM, Chen DT, Magliocco AM, Lancaster JM, Reid BM, Permuth JB. Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomes. PLoS One. 2021 Nov.16(11):e0256615. Pubmedid: 34813586. Pmcid: PMC8610269.
  • Mallen AR, Conley CC, Fuzzell L, Ketcher D, Augusto BM, McIntyre M, Barton LV, Townsend MK, Fridley BL, Tworoger SS, Wenham RM, Vadaparampil ST. "I think that a brief conversation from their provider can go a very long way": Patient and provider perspectives on barriers and facilitators of genetic testing after ovarian cancer. Support Care Cancer. 2021 May.29(5):2663-2677. Pubmedid: 32975643. Pmcid: PMC7981241.
  • Buras AL, Mallen A, Wenham R, Montejo M. Stage IIIC endometrial cancer review: Current controversies in adjuvant therapy. Gynecol Oncol Rep. 2021 May.36:100754. Pubmedid: 33869712. Pmcid: PMC8042429.
  • Biswas S, Mandal G, Payne KK, Anadon CM, Gatenbee CD, Chaurio RA, Costich TL, Moran C, Harro CM, Rigolizzo KE, Mine JA, Trillo-Tinoco J, Sasamoto N, Terry KL, Marchion D, Buras A, Wenham RM, Yu X, Townsend MK, Tworoger SS, Rodriguez PC, Anderson AR, Conejo-Garcia JR. IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature. 2021 Mar.591(7850):464-470. Pubmedid: 33536615. Pmcid: PMC7969354.
  • Mallen A, Todd S, Robertson SE, Kim J, Sehovic M, Wenham RM, Extermann M, Chon HS. Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer. Gynecol Oncol. 2021 Jun.161(3):693-699. Pubmedid: 33812698.
  • Martin A, Wells A, Anderson ML, Chern JY, Rutherford TJ, Shahzad MM, Wenham RM, Hoffman MS. Trends in ureteral surgery on an academic gynecologic oncology service. Gynecol Oncol. 2021 Dec.163(3):552-556. Pubmedid: 34674890.
  • Oza AM, Estevez-Diz M, Grischke EM, Hall M, Marmé F, Provencher D, Uyar D, Weberpals JI, Wenham RM, Laing N, Tracy M, Freshwater T, Lee MA, Liu J, Qiu J, Rose S, Rubin EH, Moore K. A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer. Clin Cancer Res. 2020 Sep.26(18):4767-4776. Pubmedid: 32611648.
  • Asamoah FA, Yarney J, Scott A, Vanderpuye V, Yuan Z, Fernandez DC, Montejo ME, Agyeman M, Boateng SN, Anarfi K, Aidoo C, Shahzad MM, Chern JY, Chon HS, Wenham RM, Yamoah K, Ahmed KA. Comparison of Definitive Cervical Cancer Management With Chemotherapy and Radiation Between Two Centers With Variable Resources and Opportunities for Improved Treatment. JCO Glob Oncol. 2020 Oct.6:1510-1518. Pubmedid: 33021855. Pmcid: PMC7605379.
  • Mu W, Liang Y, Hall LO, Tan Y, Balagurunathan Y, Wenham R, Wu N, Tian J, Gillies RJ. 18F-FDG PET/CT Habitat Radiomics Predicts Outcome of Patients with Cervical Cancer Treated with Chemoradiotherapy. Radiol Artif Intell. 2020 Nov.2(6):e190218. Pubmedid: 33937845. Pmcid: PMC8082355.
  • Mohammadi H, Prince A, Figura NB, Peacock JS, Fernandez DC, Montejo ME, Chon HS, Wenham RM, Eschrich SA, Torres-Roca JF, Ahmed KA. Using the Radiosensitivity Index (RSI) to Predict Pelvic Failure in Endometrial Cancer Treated With Adjuvant Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 Mar.106(3):496-502. Pubmedid: 31759077. Pmcid: PMC7050205.
  • Mills KA, Joshi TV, West L, Kuznicki M, Kent L, Hokenstad AN, Cripe JC, Woolfolk C, Senter L, Bakkum-Gamez JN, Wenham RM, Cohn DE, Bae-Jump V, Thaker PH. Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers?. Gynecol Oncol. 2020 Jun.157(3):706-710. Pubmedid: 32143914. Pmcid: PMC8022862.
  • Mai PL, Huang HQ, Wenzel LB, Han PK, Moser RP, Rodriguez GC, Boggess J, Rutherford TJ, Cohn DE, Kauff ND, Phillips KA, Wilkinson K, Wenham RM, Hamilton C, Powell MA, Walker JL, Greene MH, Hensley ML. Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. Gynecol Oncol. 2020 Jan.156(1):131-139. Pubmedid: 31759774. Pmcid: PMC6980744.
  • Vergote I, Heitz F, Buderath P, Powell M, Sehouli J, Lee CM, Hamilton A, Fiorica J, Moore KN, Teneriello M, Golden L, Zhang W, Pitou C, Bell R, Campbell R, Farrington DL, Bell-McGuinn K, Wenham RM. A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2020 Jan.156(1):23-31. Pubmedid: 31791552.
  • Mallen AR, Conley CC, Townsend MK, Wells A, Boac BM, Todd S, Gandhi A, Kuznicki M, Augusto BM, McIntyre M, Fridley BL, Tworoger SS, Wenham RM, Vadaparampil ST. Patterns and predictors of genetic referral among ovarian cancer patients at a National Cancer Institute-Comprehensive Cancer Center. Clin Genet. 2020 Feb.97(2):370-375. Pubmedid: 31600840. Pmcid: PMC7322721.
  • Rishi A, Rollins M, Ahmed KA, Hunt DC, Sarkar P, Fernandez DC, Hoffman MS, Apte SM, Shahzad MMK, Chon HS, Chern JY, Wenham RM, Montejo ME. High-dose intensity-modulated chemoradiotherapy in vulvar squamous cell carcinoma: Outcome and toxicity. Gynecol Oncol. 2020 Feb.156(2):349-356. Pubmedid: 31771865.
  • Saglam O, Lin DI, Steele CB, Killian JK, Wenham RM. A sporadic gastric-type endocervical adenocarcinoma with endometrial involvement and bilateral ovarian metastasis, a case report. Gynecol Oncol Rep. 2020 Apr.32:100572. Pubmedid: 32346591. Pmcid: PMC7182719.
  • Randall LM, Wenham RM, Low PS, Dowdy SC, Tanyi JL. A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer. Gynecol Oncol. 2019 Oct.155(1):63-68. Pubmedid: 31362825.
  • Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, Lesoin A, Monk BJ, Lund B, Gilbert L, Wenham RM, Benigno B, Arora S, Hazard SJ, Mirza MR. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. J Clin Oncol. 2019 Nov.37(32):2968-2973. Pubmedid: 31173551. Pmcid: PMC6839909.
  • Hoffman MS, Xiong Y, Apte S, Roberts W, Wenham RM. Twenty-year surgical trends in a gynecologic oncology fellowship training program: Implications for practice. Gynecol Oncol. 2019 Nov.155(2):359-364. Pubmedid: 31575391.
  • Fabbro M, Moore KN, Dørum A, Tinker AV, Mahner S, Bover I, Banerjee S, Tognon G, Goffin F, Shapira-Frommer R, Wenham RM, Hellman K, Provencher D, Harter P, Vázquez IP, Follana P, Pineda MJ, Mirza MR, Hazard SJ, Matulonis UA. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. Gynecol Oncol. 2019 Mar.152(3):560-567. Pubmedid: 30638768.
  • Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019 Jun.20(6):862-876. Pubmedid: 31076365.
  • Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G, Geller M, O'Malley DM, Wenham RM, Lee RB, Bodurka DC, Herzog TJ, Bookman MA. Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23]. Gynecol Oncol. 2019 Jan.152(1):220. Pubmedid: 30360899. Pmcid: PMC6321790.
  • Temkin SM, Mallen A, Bellavance E, Rubinsak L, Wenham RM. The role of menopausal hormone therapy in women with or at risk of ovarian and breast cancers: Misconceptions and current directions. Cancer. 2019 Feb.125(4):499-514. Pubmedid: 30570740.
  • Rose PG, Java JJ, Salani R, Geller MA, Secord AA, Tewari KS, Bender DP, Mutch DG, Friedlander ML, Van Le L, Method MW, Hamilton CA, Lee RB, Wenham RM, Guntupalli SR, Markman M, Muggia FM, Armstrong DK, Bookman MA, Burger RA, Copeland LJ. Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. Obstet Gynecol. 2019 Feb.133(2):245-254. Pubmedid: 30633128. Pmcid: PMC6551603.
  • Matulonis UA, Walder L, Nøttrup TJ, Bessette P, Mahner S, Gil-Martin M, Kalbacher E, Ledermann JA, Wenham RM, Woie K, Lau S, Marmé F, Casado Herraez A, Hardy-Bessard AC, Banerjee S, Lindahl G, Benigno B, Buscema J, Travers K, Guy H, Mirza MR. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial. J Clin Oncol. 2019 Dec.37(34):3183-3191. Pubmedid: 31518175. Pmcid: PMC6881097.
  • Spring BQ, Lang RT, Kercher EM, Rizvi I, Wenham RM, Conejo-Garcia JR, Hasan T, Gatenby RA, Enderling H. Illuminating the Numbers: Integrating Mathematical Models to Optimize Photomedicine Dosimetry and Combination Therapies. Front Phys. 2019 Apr.7. Pubmedid: 31123672. Pmcid: PMC6529192.
  • Nelson AM, Albizu-Jacob A, Fenech AL, Chon HS, Wenham RM, Donovan KA. Quality of life after pelvic exenteration for gynecologic cancer: Findings from a qualitative study. Psychooncology. 2018 Oct.27(10):2357-2362. Pubmedid: 29956389.
  • Mallen A, Soong TR, Townsend MK, Wenham RM, Crum CP, Tworoger SS. Surgical prevention strategies in ovarian cancer. Gynecol Oncol. 2018 Oct.151(1):166-175. Pubmedid: 30087058.
  • Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G, Geller M, O'Malley DM, Wenham RM, Lee RB, Bodurka DC, Herzog TJ, Bookman MA. Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018 Oct.151(1):18-23. Pubmedid: 30135020. Pmcid: PMC6151871.
  • Bishop EA, Java JJ, Moore KN, Spirtos NM, Pearl ML, Zivanovic O, Kushner DM, Backes F, Hamilton CA, Geller MA, Hurteau J, Mathews C, Wenham RM, Ramirez PT, Zweizig S, Walker JL. Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol. 2018 Jan.218(1):109.e1-109.e11. Pubmedid: 29037481. Pmcid: PMC5756682.
  • Kang S, Thompson Z, McClung EC, Abdallah R, Lee JK, Gonzalez-Bosquet J, Wenham RM, Chon HS. Gene Expression Signature-Based Prediction of Lymph Node Metastasis in Patients With Endometrioid Endometrial Cancer. Int J Gynecol Cancer. 2018 Feb.28(2):260-266. Pubmedid: 29194195. Pmcid: PMC5780243.
  • Boac BM, Xiong Y, Apte SM, Wenham RM, Shahzad MM, Munroe DG, Lancaster JM, Chon HS. Adherence to practice guidelines is associated with reduced referral times for patients with ovarian cancer. Am J Obstet Gynecol. 2018 Apr.218(4):436.e1-436.e7. Pubmedid: 29353030.
  • Moore KN, Tritchler D, Kaufman KM, Lankes H, Quinn MCJ, Van Le L, Berchuck A, Backes FJ, Tewari KS, Lee RB, Kesterson JP, Wenham RM, Armstrong DK, Krivak TC, Bookman MA, Birrer MJ. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 Nov.147(2):396-401. Pubmedid: 28935272. Pmcid: PMC5706110.
  • Rungruang BJ, Miller A, Krivak TC, Horowitz NS, Rodriguez N, Hamilton CA, Backes FJ, Carson LF, Friedlander M, Mutch DG, Goodheart MJ, Tewari KS, Wenham RM, Bookman MA, Maxwell GL, Richard SD. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. Cancer. 2017 May.123(6):985-993. Pubmedid: 27864921. Pmcid: PMC5339038.
  • Chon HS, Kang S, Lee JK, Apte SM, Shahzad MM, Williams-Elson I, Wenham RM. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers. BMC Cancer. 2017 Jun.17(1):407. Pubmedid: 28595616. Pmcid: PMC5465458.
  • Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, Kurzeder C, Colombo N, Vuylsteke P, Lorusso D, Hall M, Renard V, Pignata S, Kristeleit R, Altintas S, Rustin G, Wenham RM, Mirza MR, Fong PC, Oza A, Monk BJ, Ma H, Vogl FD, Bach BA. ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. Eur J Cancer. 2017 Jan.70:111-121. Pubmedid: 27914241.
  • Saglam O, Xiong Y, Marchion DC, Strosberg C, Wenham RM, Johnson JJ, Saeed-Vafa D, Cubitt C, Hakam A, Magliocco AM. ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy. Cancer Control. 2017 Jan.24(1):89-95. Pubmedid: 28178720. Pmcid: PMC7771303.
  • Makker V, Green AK, Wenham RM, Mutch D, Davidson B, Miller DS. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecol Oncol Res Pract. 2017 Dec.4:19. Pubmedid: 29214032. Pmcid: PMC5712183.
  • Mai PL, Piedmonte M, Han PK, Moser RP, Walker JL, Rodriguez G, Boggess J, Rutherford TJ, Zivanovic O, Cohn DE, Thigpen JT, Wenham RM, Friedlander ML, Hamilton CA, Bakkum-Gamez J, Olawaiye AB, Hensley ML, Greene MH, Huang HQ, Wenzel L. Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 Apr.145(1):122-129. Pubmedid: 28190649. Pmcid: PMC5359045.
  • Abdallah R, Bush SH, Chon HS, Apte SM, Wenham RM, Shahzad MM. Therapeutic Dilemma: Prognostic Factors and Outcome for Neuroendocrine Tumors of the Cervix. Int J Gynecol Cancer. 2016 Mar.26(3):553-560. Pubmedid: 26825841.
  • Bush SH, Tollin S, Marchion DC, Xiong Y, Abbasi F, Ramirez IJ, Zgheib NB, Boac B, Judson PL, Chon HS, Wenham RM, Apte SM, Cubitt CL, Berglund AE, Havrilesky LJ, Lancaster JM. Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival. Mol Clin Oncol. 2016 Mar.4(3):399-404. Pubmedid: 26998291. Pmcid: PMC4774474.
  • McClung EC, Wenham RM. Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives. Int J Womens Health. 2016 Mar.8:59-75. Pubmedid: 27051317. Pmcid: PMC4803258.
  • Bou Zgheib N, Marchion DC, Bush SH, Judson PL, Wenham RM, Apte SM, Lancaster JM, Gonzalez-Bosquet J. Molecular determinants for lymph node metastasis in clinically early-stage endometrial cancer. Oncol Lett. 2016 Jan.11(1):323-329. Pubmedid: 26870211. Pmcid: PMC4726972.
  • Boac BM, Xiong Y, Marchion DC, Abbasi F, Bush SH, Ramirez IJ, Khulpateea BR, Clair McClung E, Berry AL, Zgheib NB, Chon HS, Shahzad MM, Judson PL, Wenham RM, Apte SM, Berglund AE, Magliocco AM, Lancaster JM. Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance. Gynecol Oncol. 2016 Feb.140(2):259-263. Pubmedid: 26731723. Pmcid: PMC4724442.
  • Abdallah R, Chon HS, Bou Zgheib N, Marchion DC, Wenham RM, Lancaster JM, Gonzalez-Bosquet J. Prediction of Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression Data. Int J Gynecol Cancer. 2015 Jul.25(6):1000-1009. Pubmedid: 26098088.
  • Sawah EA, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, Boac BM, Bush SH, Zgheib NB, McClung EC, Khulpateea BR, Berry A, Hakam A, Wenham RM, Lancaster JM, Judson PL. The Chinese herb polyphyllin D sensitizes ovarian cancer cells to cisplatin-induced growth arrest. J Cancer Res Clin Oncol. 2015 Feb.141(2):237-242. Pubmedid: 25164128.
  • Ebbert JA, Donovan KA, Lengacher CA, Fabri D, Reich R, Daley E, Thompson EL, Wenham RM. Right Place, Right Time: Preferences of Women with Ovarian Cancer for Delivery of CAM Education. Medicines (Basel). 2015 Aug.2(3):236-250. Pubmedid: 28930210. Pmcid: PMC5456219.
  • Stickles XB, Marchion DC, Bicaku E, Al Sawah E, Abbasi F, Xiong Y, Bou Zgheib N, Boac BM, Orr BC, Judson PL, Berry A, Hakam A, Wenham RM, Apte SM, Berglund AE, Lancaster JM. BAD-mediated apoptotic pathway is associated with human cancer development. Int J Mol Med. 2015 Apr.35(4):1081-1087. Pubmedid: 25653146. Pmcid: PMC4356438.
  • Vergote I, Schilder RJ, Pippitt CH, Wong S, Gordon AN, Scudder S, Kridelka F, Dirix L, Leach JW, Ananda S, Nanayakkara N, Melara R, Bass MB, Litten J, Adewoye H, Wenham RM. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. Gynecol Oncol. 2014 Oct.135(1):25-33. Pubmedid: 25019569.
  • Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Brit J Cancer. 2014 Nov.111(10):1932-1944. Pubmedid: 25290091. Pmcid: PMC4229637.
  • Dobrinski K, Esposito NN, Kruk PA, Wenham R, Hoffman M, Coppola D, Bai W, Zhang X, Siddique N, Nicosia SV. Procurement and cytological features of human fallopian tube fimbrial cells by ex vivo imprinting and washing. J Am Soc Cytopathol. 2014 Nov.3(6):309-318. Pubmedid: 31051721.
  • Herzog TJ, Monk BJ, Rose PG, Braly P, Hines JF, Bell MC, Wenham RM, Secord AA, Roman LD, Einstein MH, Drake RD, Childs BH. A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. Gynecol Oncol. 2014 Mar.132(3):517-525. Pubmedid: 24476788. Pmcid: PMC5718618.
  • Chen N, Chon HS, Xiong Y, Marchion DC, Judson PL, Hakam A, Gonzalez-Bosquet J, Permuth-Wey J, Wenham RM, Apte SM, Cheng JQ, Sellers TA, Lancaster JM. Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Oncol Rep. 2014 Jan.31(1):376-383. Pubmedid: 24220856. Pmcid: PMC3981115.
  • Schwandt A, von Gruenigen VE, Wenham RM, Frasure H, Eaton S, Fusco N, Fu P, Wright JJ, Dowlati A, Waggoner S. Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer. Invest New Drugs. 2014 Aug.32(4):729-738. Pubmedid: 24619298.
  • Al Sawah E, Chen X, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, Zgheib NB, Chon HS, Wenham RM, Apte SM, Judson PL, Lancaster JM. Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest. Gynecol Oncol. 2013 Oct.131(1):207-212. Pubmedid: 23877012.
  • Marchion DC, Bicaku E, Xiong Y, Zgheib NB, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster JM. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May.29(5):2011-2018. Pubmedid: 23467907. Pmcid: PMC4536335.
  • Teefey P, Zgheib NB, Apte SM, Gonzalez-Bosquet J, Judson PL, Roberts WS, Lancaster JM, Wenham RM. Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers. Am J Obstet Gynecol. 2013 Jun.208(6):501.e1-501.e7. Pubmedid: 23507546.
  • Jim H, Barata A, Wenham R, Jacobsen P. Fatigue, Mood, and Sleep, During Intraperitoneal Chemotherapy: A Pilot Case Control Study. Int J Psychol Res (Medellin). 2013 Jun.6(1):8-14. Pubmedid: 25374652. Pmcid: PMC4217125.
  • Jim HS, Jacobsen PB, Phillips KM, Wenham RM, Roberts W, Small BJ. Lagged relationships among sleep disturbance, fatigue, and depressed mood during chemotherapy. Health Psychol. 2013 Jul.32(7):768-774. Pubmedid: 23437852. Pmcid: PMC3700563.
  • Wenham RM, Lapolla J, Lin HY, Apte SM, Lancaster JM, Judson PL, Gonzalez-Bosquet J, Herschberger A, Havrilesky LJ, Secord AA. A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. Gynecol Oncol. 2013 Jul.130(1):19-24. Pubmedid: 23623830.
  • Rodriguez GC, Barnes HJ, Anderson KE, Whitaker RS, Berchuck A, Petitte JN, Lancaster JM, Wenham RM, Turbov JM, Day R, Maxwell GL, Carver DK. Evidence of a Chemopreventive Effect of Progestin Unrelated to Ovulation on Reproductive Tract Cancers in the Egg-laying Hen. Cancer Prev Res (Phila). 2013 Dec.6(12):1283-1292. Pubmedid: 24136864.
  • Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013 Aug.14(9):882-892. Pubmedid: 23810788.
  • Secord AA, Teoh DK, Barry WT, Yu M, Broadwater G, Havrilesky LJ, Lee PS, Berchuck A, Lancaster J, Wenham RM. A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. Clin Cancer Res. 2012 Oct.18(19):5489-5498. Pubmedid: 22837181. Pmcid: PMC3463759.
  • Xu CX, Xu M, Tan L, Yang H, Permuth-Wey J, Kruk PA, Wenham RM, Nicosia SV, Lancaster JM, Sellers TA, Cheng JQ. MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog. J Biol Chem. 2012 Oct.287(42):34970-34978. Pubmedid: 22927443. Pmcid: PMC3471722.
  • Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Fulp W, Cubitt CL, Chen DT, Lancaster JM. In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival. Brit J Cancer. 2012 Jun.106(12):1967-1975. Pubmedid: 22596241. Pmcid: PMC3388569.
  • Zgheib NB, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Cubitt CL, Chen DT, Lancaster JM. The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer. Int J Oncol. 2012 Jul.41(1):179-188. Pubmedid: 22552627. Pmcid: PMC4017641.
  • Judson PL, Al Sawah E, Marchion DC, Xiong Y, Bicaku E, Zgheib NB, Chon HS, Stickles XB, Hakam A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Chen DT, Lancaster JM. Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity. Int J Gynecol Cancer. 2012 Jul.22(6):960-967. Pubmedid: 22740002. Pmcid: PMC4036555.
  • Chon HS, Marchion DC, Xiong Y, Chen N, Bicaku E, Stickles XB, Zgheib NB, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Lancaster JM. The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin. Gynecol Oncol. 2012 Jan.124(1):119-124. Pubmedid: 22032837. Pmcid: PMC8744065.
  • Bansal N, Marchion DC, Bicaku E, Xiong Y, Chen N, Stickles XB, Sawah EA, Wenham RM, Apte SM, Gonzalez-Bosquet J, Judson PL, Hakam A, Lancaster JM. BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. J Gynecol Oncol. 2012 Jan.23(1):35-42. Pubmedid: 22355465. Pmcid: PMC3280065.
  • Wenham RM, Sullivan DM, Hulse M, Jacobsen PB, Dalton WS. The creation of an integrated health-information platform: building the framework to support personalized medicine. Per Med. 2012 Aug.9(6):621-632. Pubmedid: 29768801.
  • Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, Berchuck A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Bloom GC, Eschrich SA, Sebti S, Chen DT, Lancaster JM. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res. 2011 Oct.17(19):6356-6366. Pubmedid: 21849418. Pmcid: PMC3186862.
  • Wenham RM. Ovarian cancer: a bright future. Cancer Control. 2011 Jan.18(1):4-5. Pubmedid: 21273974.
  • Garrett CR, Coppola D, Wenham RM, Cubitt CL, Neuger AM, Frost TJ, Lush RM, Sullivan DM, Cheng JQ, Sebti SM. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs. 2011 Dec.29(6):1381-1389. Pubmedid: 20644979. Pmcid: PMC4612514.
  • Indermaur MD, Xiong Y, Kamath SG, Boren T, Hakam A, Wenham RM, Apte SM, Lancaster JM. Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin. Am J Obstet Gynecol. 2010 Aug.203(2):158.e1-158.40. Pubmedid: 20444440.
  • Bansal N, Roberts WS, Apte SM, Lancaster JM, Wenham RM. Electrothermal bipolar coagulation decreases the rate of red blood cell transfusions for pelvic exenterations. J Surg Oncol. 2009 Nov.100(6):511-514. Pubmedid: 19697350.
  • Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, Kamath SG, Chen DT, Dressman H, Lancaster JM. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol. 2009 May.113(2):249-255. Pubmedid: 19237188.
  • Hoffman MS, Ondrovic LE, Wenham RM, Apte SM, Shames ML, Zervos EE, Weinberg WS, Roberts WS. Evaluation of the porcine model to teach various ancillary procedures to gynecologic oncology fellows. Am J Obstet Gynecol. 2009 Jul.201(1):116.e1-116.e3. Pubmedid: 19576378.
  • Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009 Jan.16(1):8-13. Pubmedid: 19078924.
  • Marquez CB, Smithberger EE, Bair SM, Wenham RM, Fenske NA, Glass LF, Cherpelis BS. Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene. Cancer Control. 2009 Jan.16(1):66-69. Pubmedid: 19078932.
  • Wenham RM. Endometrial cancer: contemporary insights into our most common gynecologic cancer. Cancer Control. 2009 Jan.16(1):4-5. Pubmedid: 19078923.
  • Hakim AA, Barry CP, Barnes HJ, Anderson KE, Petitte J, Whitaker R, Lancaster JM, Wenham RM, Carver DK, Turbov J, Berchuck A, Kopelovich L, Rodriguez GC. Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu. Cancer Prev Res (Phila). 2009 Feb.2(2):114-121. Pubmedid: 19174584.
  • Kamath SG, Chen N, Xiong Y, Wenham R, Apte S, Humphrey M, Cragun J, Lancaster JM. Gedunin, a novel natural substance, inhibits ovarian cancer cell proliferation. Int J Gynecol Cancer. 2009 Dec.19(9):1564-1569. Pubmedid: 19955938.
  • Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008 Jan.68(2):425-433. Pubmedid: 18199536.
  • Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, Kamath S, Chen D, Dressman H, Lancaster J. MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol. 2008 Aug.110(2):206-215. Pubmedid: 18499237.
  • Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007 Nov.25(33):5180-5186. Pubmedid: 18024865.
  • Hoyo C, Grubber J, Demark-Wahnefried W, Marks JR, Freedland SJ, Jeffreys AS, Grambow SC, Wenham RM, Walther PJ, Schildkraut JM. Grade-specific prostate cancer associations of IGF1 (CA)19 repeats and IGFBP3-202A/C in blacks and whites. J Natl Med Assoc. 2007 Jul.99(7):718-722. Pubmedid: 17668637. Pmcid: PMC2574361.
  • Donovan K, Taliaferro L, Alvarez E, Jacobsen P, Roetzheim R, Wenham R. Sexual health in women treated for cervical cancer: characteristics and correlates. Gynecol Oncol. 2007 Feb.104(2):428-434. Pubmedid: 17005248.
  • Berchuck A, Schildkraut JM, Wenham RM, Calingaert B, Ali S, Henriott A, Halabi S, Rodriguez GC, Gertig D, Purdie DM, Kelemen L, Spurdle AB, Marks J, Chenevix-Trench G. Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. Cancer Epidemiol Biomarkers Prev. 2004 Dec.13(12):2141-2147. Pubmedid: 15598772.
  • Wenham R, Calingaert B, Ali S, McClean K, Whitaker R, Bentley R, LancasterJM, Schildkraut J, Marks J, Berchuck A. Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer. J Soc Gynecol Investig. 2003 Sep.10(6):381-387. Pubmedid: 12969782.
  • Wenham R, Schildkraut J, McLean K, Calingaert B, Bentley R, Marks J, Berchuck A. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Clin Cancer Res. 2003 Oct.9(12):4396-4403. Pubmedid: 14555511.
  • Garrett A, Wenham R, Sheets E. Monsel's Solution: A Brief History. J Low Genit Tract Dis. 2002 Oct.6(4):225-227. Pubmedid: 17051027.
  • Garrett A, Wenham R, Onderdonk A, Sheets E. Can Monsel's Transmit Nosocomial Infections? A Microbiological Investigation. J Low Genit Tract Dis. 2002 Oct.6(4):228-231. Pubmedid: 17051028.
  • Wenham R, Lancaster J, Berchuck A. Molecular aspects of ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2002 Aug.16(4):483-497. Pubmedid: 12413930.
  • Lea J, Sheets E, Wenham R, Duska L, Coleman R, Miller D, Schorge J. Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. Gynecol Oncol. 2002.84(1):115-119. Pubmedid: 11748986.
  • Wenham RM, Landt M, Easom RA. Glucose activates the multifunctional Ca2+/calmodulin-dependent protein kinase II in isolated rat pancreatic islets. J Biol Chem. 1994 Feb.269(7):4947-4952. Pubmedid: 8106469.
  • Wenham RM, Landt M, Walters SM, Hidaka H, Easom RA. Inhibition of insulin secretion by KN-62, a specific inhibitor of the multifunctional Ca2+/calmodulin-dependent protein kinase II. Biochem Bioph Res Co. 1992 Nov.189(1):128-133. Pubmedid: 1333187.
  • Fenstermacher DA, Wenham RM, Rollison DE, Dalton WS. Implementing personalized medicine in a cancer center. Cancer J. 17(6):528-536. Pubmedid: 22157297. Pmcid: PMC3240816.

Patient Comments
Overall Satisfaction
4.9
★★★★★
★★★★★

116 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments